TY - JOUR
T1 - Diagnostic accuracy of PIVKA-II, alpha-fetoprotein and a combination of both in diagnosis of hepatocellular carcinoma in patients affected by chronic HCV infection
AU - Gentile, Ivan
AU - Buonomo, Antonio Riccardo
AU - Scotto, Riccardo
AU - Zappulo, Emanuela
AU - Carriero, Canio
AU - Piccirillo, Mauro
AU - Izzo, Francesco
AU - Rizzo, Marianna
AU - Cerasuolo, Dionigio
AU - Borgia, Guglielmo
AU - Cavalcanti, Ernesta
PY - 2017/7/1
Y1 - 2017/7/1
N2 - are at high risk for developing hepatocellular carcinoma (HCC). The aim of this study was to evaluate the feasibility of PIVKA-II (protein induced by Vitamin K absence or antagonist-II) alone or in combination with α-1 fetoprotein (AFP), as a screening marker for development of HCC. Materials and Methods: A case-control study was conducted in 2 hospital wards in Naples. All anti-HCV-positive patients affected by HCC were considered as cases, while consecutive anti-HCV-positive patients without HCC were considered as controls. Results: Overall, 160 patients were enrolled, 56 cases and 104 controls. At the set cut-off of 36 mAU/ml, PIVKA-II was more sensitive (78.6% vs. 60%), but less specific than AFP at the set cut-off of 12 ng/ml (66.3% vs. 77.2%). The negative predictive value of PIVKA in combination with AFP was 93.2%. Conclusion: PIVKA II, when combined with AFP, may be considered as a screening test for HCC due to its high negative predictive value.
AB - are at high risk for developing hepatocellular carcinoma (HCC). The aim of this study was to evaluate the feasibility of PIVKA-II (protein induced by Vitamin K absence or antagonist-II) alone or in combination with α-1 fetoprotein (AFP), as a screening marker for development of HCC. Materials and Methods: A case-control study was conducted in 2 hospital wards in Naples. All anti-HCV-positive patients affected by HCC were considered as cases, while consecutive anti-HCV-positive patients without HCC were considered as controls. Results: Overall, 160 patients were enrolled, 56 cases and 104 controls. At the set cut-off of 36 mAU/ml, PIVKA-II was more sensitive (78.6% vs. 60%), but less specific than AFP at the set cut-off of 12 ng/ml (66.3% vs. 77.2%). The negative predictive value of PIVKA in combination with AFP was 93.2%. Conclusion: PIVKA II, when combined with AFP, may be considered as a screening test for HCC due to its high negative predictive value.
KW - AFP
KW - Cirrhosis
KW - HCC
KW - HCV
KW - PIVKA-II
UR - http://www.scopus.com/inward/record.url?scp=85028522683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028522683&partnerID=8YFLogxK
U2 - 10.21873/invivo.11115
DO - 10.21873/invivo.11115
M3 - Article
AN - SCOPUS:85028522683
VL - 31
SP - 695
EP - 700
JO - In Vivo
JF - In Vivo
SN - 0258-851X
IS - 4
ER -